Effectiveness of BNT162b2 vaccine against critical COVID-19 in adolescents
New England Journal of Medicine — Olson SM, Newhams MM, Halasa NB, et al. | January 14, 2022
The United States showed an increasing incidence of pediatric hospitalizations linked with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This provides an opportunity to determine the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.
A case–control, test-negative design was used. Among 445 case patients and 777 controls, 17 case patients (4%) and 282 controls (36%) had been fully vaccinated.
The BNT162b2 vaccine showed an overall effectiveness of 94% against hospitalization for Covid-19.
Overall observations suggest a great effectiveness of two doses of the BNT162b2 vaccine against Covid-19–related hospitalization and ICU admission or the receipt of life support.